Marker Therapeutics, Inc.
MRKR· Nasdaq
MRKRMarker Therapeutics, Inc.
Released Aug 10, 2021, after the close
10-Q filed Aug 10, 2021, 41 days after period end · 0001104659-21-102826
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | — | $466.79K | $0.00 | $205.99K |
| Net Income | -$10.91M | -$6.34M | -$5.57M | -$4.81M |
| EPS Diluted |
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
| -$0.13 |
| -$0.14 |
| -$0.12 |
| -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
